ALK+ S-ALCL may have a more favorable clinical course than ALK- S-ALCL [6-8], but recent study found that activation of ALK could provides oncogenic addiction to tumors harboring activating mutation or translocation of ALK such as in non-small cell lung cancer, so ALK inhibitor may be a potent novel targeted therapeutic in some solid tumor [34]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.